Bumped- cause of new info link concerning 'Flare issues' found in about
1/3 of patients using this, via scans this was found:
The results of the study showed the following:
•22/33 patients (67 percent) had a PSA decline of ≥ 50 percent at week 12.
•26/33 patients (76 percent) had a PSA decline of ≥ 50 percent overall.
•Undetectable PSA levels (≤ 0.1 ng/ml) were documented in two patients.
•Average (median) time on therapy was 63 weeks.
•Average (median) time to PSA progression was 16.3 months.
•23/33 patients (70 percent) were evaluable for bone scan flare.
◦12/23 evaluable patients (52 percent) showed disease progression on bone scan, as indicated in radiologists’ reports.
◦11/12 patients showing signs of progression subsequently showed improvement or stability.•As defined above, bone scan flare was observed in 11/23 evaluable patients (48 percent) or 11/33 enrolled patients (patients).
•Adverse events to abiraterone therapy were typically grade 1/2 and were consistent with adverse events in prior published reportshttp://prostatecancerinfolink.net/
(the source of this claim and quoted studieds above)